Cost of lung cancer diagnosis: cost differences between national health system and private sector [0.03%]
肺癌诊断费用：国立医疗体系与私营部门之比较
Paul Zarogoulidis,Vasilis Papadopoulos,Eleni-Isidora Perdikouri et al.
Paul Zarogoulidis et al.
Introduction: Lung cancer is still diagnosed at an advanced stage due to lack of early disease symptoms. Areas covered: We have techniques and equipment for rapid on site evaluation of pulmonary lesions. However, with new technology or a co...
Lung cancer patients with anaplastic lymphoma kinase rearrangement lose affiliation with labor market at diagnosis [0.03%]
ROS1重排型肺癌患者在确诊时已脱离劳动市场
Jon Lykkegaard Andersen,Jakob Sidenius Johansen,Edyta Maria Urbanska et al.
Jon Lykkegaard Andersen et al.
Aim: The main purpose of the present study was to investigate the labor market affiliation of ALK+ NSCLC patients in long-term treatment as well as overall survival and incidence/prevalence. Materials & methods: Nationwide retrospective stu...
Mehmet Emin Buyukbayram,Zekeriya Hannarici,Ali Yilmaz et al.
Mehmet Emin Buyukbayram et al.
Aim: The tumor microenvironment of NSCLC with driver mutations, such as EGFR, ALK and ROS, is less inflammatory. Materials & methods: This retrospective study included 38 patients with NSCLC driver mutations. The relationship between clinic...
Achieving long-term survival in extensive-stage SCLC: a case report and mini literature review [0.03%]
广泛期小细胞肺癌长期生存的病例报告及文献综述
Yayun Mao,Meiping Huang,Jiafu Liu
Yayun Mao
Managing extensive-stage SCLC (ES-SCLC) has long been challenging for clinicians and oncologists due to its aggressive nature and poor prognosis. We report a case of a 41-year-old female with ES-SCLC who survived for six years, defying the ...
Diagnostic value of combined detection of plasma cfDNA concentration and integrity in NSCLC [0.03%]
血浆cfDNA浓度和完整性联合检测在NSCLC诊断中的价值
Sai Ren,Chunli Yu,Qing Huang
Sai Ren
Aim: To evaluate the value of combined detection of plasma cfDNA concentration and integrity in the early diagnosis of NSCLC. Methods: Real-time fluorescence quantitative PCR was used to determine the concentration and integrity of plasma c...
Prognostic significance of systemic immune inflammatory index in NSCLC: a meta-analysis [0.03%]
系统免疫炎症指数在非小细胞肺癌中的预后价值：一项meta分析研究
Wen-Hua Chen,Jing-Jing Shao,Ying Yang et al.
Wen-Hua Chen et al.
Aim: The aim of this meta-analysis was to investigate the relationship between the baseline systemic immune inflammatory index (SII) and prognosis in patients with NSCLC. Materials & methods: The relation between pretreatment SII and overal...
A retrospective study of ensartinib-treated ALK-positive locally advanced or metastatic NSCLC patients in China [0.03%]
艾森坦治疗的ALK阳性的局部晚期或转移性非小细胞肺癌中国患者的回顾性研究
Xiaobin Yuan,Yang Wang,Min Yang et al.
Xiaobin Yuan et al.
Aim: This retrospective study aimed to assess the efficacy and safety of ensartinib in Chinese patients with ALK-positive advanced NSCLC in real-world clinical practice. ...
Huajian Liu,Liam Polley
Huajian Liu
Aim: Multiple primary lung cancers are becoming increasingly recognised and pose diagnostic and staging uncertainties with challenging management options and prognostication. ...
Increased sympathetic nervous system impairs prognosis in lung cancer patients: a scoping review of clinical studies [0.03%]
交感神经系统的增强会损害肺癌患者的预后：临床研究的范围审查
Fabrício T Garramona,Telma F Cunha,Janaína S Vieira et al.
Fabrício T Garramona et al.
Aim: To summarize current knowledge, gaps, quality of the evidence and show main results related to the role of the autonomic nervous system in lung cancer. ...
Survival and quality-of-life outcomes in early-stage NSCLC patients: a literature review of real-world evidence [0.03%]
早期NSCLC患者生存率和生活质量的预后研究：基于真实世界证据的文献回顾
Nick Jovanoski,Kathleen Bowes,Audrey Brown et al.
Nick Jovanoski et al.
Aim: Assess the long-term survival and quality-of-life outcomes in early-stage NSCLC (eNSCLC) patients. Methods: Review of long-term su...